Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis

Biochimie

Volumn 89, Issue 10, 2007, Pages 1234-1244

  Hadj Slimane, Réda ^a,b   Lepelletier, Yves ^a   Lopez, Nicolas ^a,b   Garbay, Christiane ^a,b   Raynaud, Françoise ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

Author keywords

Age related macular degeneration; Angiogenesis; Cancer; siRNA; VEGF

Indexed keywords

LIPOSOME; PEGAPTANIB; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; DIABETIC RETINOPATHY; DRUG TARGETING; GENE FUNCTION; GENE SILENCING; HUMAN; LIPOSOMAL DELIVERY; LIPOSOMAL GENE DELIVERY SYSTEM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; PSORIASIS; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; RNA TRANSLATION; SIGNAL TRANSDUCTION;

HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA;

EID: 34848851014     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2007.06.012     Document Type: Review

References (113)

1. Eliceiri B.P., and Cheresh D.A. Adhesion events in angiogenesis. Curr. Opin. Cell Biol. 13 (2001) 563-568
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med 1 (1995) 27-31
3. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
4. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
5. Klagsbrun M., and Moses M.A. Molecular angiogenesis. Chem. Biol. 6 (1999) R217-R224
6. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol 237 (1999) 97-132
7. Kaipainen A., Korhonen J., Mustonen T., van Hinsbergh V.W., Fang G.H., Dumont D., Breitman M., and Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA 92 (1995) 3566-3570
8. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., and Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269 (1994) 26988-26995
9. Soker S., Takashima S., Miao H.Q., Neufeld G., and Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92 (1998) 735-745
10. Whitaker G.B., Limberg B.J., and Rosenbaum J.S. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). J. Biol. Chem. 276 (2001) 25520-25531
11. Iliopoulos O., Levy A.P., Jiang C., Kaelin Jr. W.G., and Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA 93 (1996) 10595-10599
12. Dor V., and Di Donato M. Ventricular remodeling in coronary artery disease. Curr. Opin. Cardiol 12 (1997) 533-537
13. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
14. Millauer B., Shawver L.K., Plate K.H., Risau W., and Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367 (1994) 576-579
15. Kendall R.L., Wang G., and Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun 226 (1996) 324-328
16. Ng E.W., and Adamis A.P. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann. NY Acad. Sci. 1082 (2006) 151-171
17. Fischer B., Marinov M., and Arcaro A. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?. Cancer Treat. Rev. 33 4 (2007) 391-406 Epub 2007 Mar 26
18. Lu P.Y., Xie F.Y., and Woodle M.C. siRNA-mediated antitumorigenesis for drug target validation and therapeutics. Curr. Opin. Mol. Ther 5 (2003) 225-234
19. Rana T.M. Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 8 (2007) 23-36
20. Napoli C., Lemieux C., and Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2 (1990) 279-289
21. Zamore P.D. RNA interference: big applause for silencing in Stockholm. Cell 127 (2006) 1083-1086
22. Lee Y.S., Nakahara K., Pham J.W., Kim K., He Z., Sontheimer E.J., and Carthew R.W. Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell 117 (2004) 69-81
23. Gregory R.I., Chendrimada T.P., Cooch N., and Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123 (2005) 631-640
24. Tomari Y., Du T., Haley B., Schwarz D.S., Bennett R., Cook H.A., Koppetsch B.S., Theurkauf W.E., and Zamore P.D. RISC assembly defects in the Drosophila RNAi mutant armitage. Cell 116 (2004) 831-841
25. Kim B., Tang Q., Biswas P.S., Xu J., Schiffelers R.M., Xie F.Y., Ansari A.M., Scaria P.V., Woodle M.C., Lu P., and Rouse B.T. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol 165 (2004) 2177-2185
26. Reich S.J., Fosnot J., Kuroki A., Tang W., Yang X., Maguire A.M., Bennett J., and Tolentino M.J. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis 9 (2003) 210-216
27. Song E., Zhu P., Lee S.K., Chowdhury D., Kussman S., Dykxhoorn D.M., Feng Y., Palliser D., Weiner D.B., Shankar P., Marasco W.A., and Lieberman J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol 23 (2005) 709-717
28. Faltus T., Yuan J., Zimmer B., Kramer A., Loibl S., Kaufmann M., and Strebhardt K. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 6 (2004) 786-795
29. Fu G.F., Lin X.H., Han Q.W., Fan Y.R., Xu Y.F., Guo D., Xu G.X., and Hou Y.Y. RNA interference remarkably suppresses bcl-2 gene expression in cancer cells in vitro and in vivo. Cancer Biol. Ther 4 (2005) 822-829
30. Lima R.T., Martins L.M., Guimaraes J.E., Sambade C., and Vasconcelos M.H. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 11 (2004) 309-316
31. McManus D.C., Lefebvre C.A., Cherton-Horvat G., St-Jean M., Kandimalla E.R., Agrawal S., Morris S.J., Durkin J.P., and Lacasse E.C. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 23 (2004) 8105-8117
32. Sumimoto H., Miyagishi M., Miyoshi H., Yamagata S., Shimizu A., Taira K., and Kawakami Y. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23 (2004) 6031-6039
33. Sumimoto H., Imabayashi F., Iwata T., and Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med 203 (2006) 1651-1656
34. Eskandarpour M., Kiaii S., Zhu C., Castro J., Sakko A.J., and Hansson J. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int. J. Cancer 115 (2005) 65-73
35. Minakuchi Y., Takeshita F., Kosaka N., Sasaki H., Yamamoto Y., Kouno M., Honma K., Nagahara S., Hanai K., Sano A., Kato T., Terada M., and Ochiya T. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 32 (2004) e109
36. Santel A., Aleku M., Keil O., Endruschat J., Esche V., Fisch G., Dames S., Loffler K., Fechtner M., Arnold W., Giese K., Klippel A., and Kaufmann J. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 13 (2006) 1222-1234
37. Ning S., Fuessel S., Kotzsch M., Kraemer K., Kappler M., Schmidt U., Taubert H., Wirth M.P., and Meye A. siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int. J. Oncol 25 (2004) 1065-1071
38. Moshfeghi A.A., Rosenfeld P.J., Puliafito C.A., Michels S., Marcus E.N., Lenchus J.D., and Venkatraman A.S. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113 (2006) e2001-e2012 2002
39. Holmqvist K., Cross M.J., Rolny C., Hagerkvist R., Rahimi N., Matsumoto T., Claesson-Welsh L., and Welsh M. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J. Biol. Chem. 279 (2004) 22267-22275
40. Cashman S.M., Bowman L., Christofferson J., and Kumar-Singh R. Inhibition of choroidal neovascularization by adenovirus-mediated delivery of short hairpin RNAs targeting VEGF as a potential therapy for AMD. Invest. Ophthalmol. Vis. Sci. 47 (2006) 3496-3504
41. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., Molema G., Lu P.Y., Scaria P.V., and Woodle M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32 (2004) e149
42. Kim D.H., and Rossi J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8 (2007) 173-184
43. Fattal E., and Bochot A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv. Drug Deliv. Rev. 58 (2006) 1203-1223
44. Nickoloff B.J. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J. Investig. Dermatol. Symp. Proc. 5 (2000) 67-73
45. Detmar M. Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis. J. Invest. Dermatol 122 (2004) xiv-xv
46. Dowds T.A., Masumoto J., Zhu L., Inohara N., and Nunez G. Cryopyrin-induced interleukin 1beta secretion in monocytic cells: enhanced activity of disease-associated mutants and requirement for ASC. J. Biol. Chem. 279 (2004) 21924-21928
47. Kim W.U., Kang S.S., Yoo S.A., Hong K.H., Bae D.G., Lee M.S., Hong S.W., Chae C.B., and Cho C.S. Interaction of vascular endothelial growth factor 165 with neuropilin-1 protects rheumatoid synoviocytes from apoptotic death by regulating Bcl-2 expression and Bax translocation. J. Immunol 177 (2006) 5727-5735
48. Miyashita T., Kawakami A., Tamai M., Izumi Y., Mingguo H., Tanaka F., Abiru S., Nakashima K., Iwanaga N., Aratake K., Kamachi M., Arima K., Ida H., Migita K., Origuchi T., Tagashira S., Nishikaku F., and Eguchi K. Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells. Biochem. Biophys. Res. Commun 312 (2003) 397-404
49. Johansen C., Funding A.T., Otkjaer K., Kragballe K., Jensen U.B., Madsen M., Binderup L., Skak-Nielsen T., Fjording M.S., and Iversen L. Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J. Immunol 176 (2006) 1431-1438
50. Funding A.T., Johansen C., Kragballe K., Otkjaer K., Jensen U.B., Madsen M.W., Fjording M.S., Finnemann J., Skak-Nielsen T., Paludan S.R., and Iversen L. Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. J. Invest. Dermatol 126 (2006) 1784-1791
51. Xie F.Y., Woodle M.C., and Lu P.Y. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov. Today 11 (2006) 67-73
52. Schulze-Bergkamen H., Fleischer B., Schuchmann M., Weber A., Weinmann A., Krammer P.H., and Galle P.R. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer 6 (2006) 232
53. Spagnuolo R., Corada M., Orsenigo F., Zanetta L., Deuschle U., Sandy P., Schneider C., Drake C.J., Breviario F., and Dejana E. Gas1 is induced by VE-cadherin and vascular endothelial growth factor and inhibits endothelial cell apoptosis. Blood 103 (2004) 3005-3012
54. Calipel A., Lefevre G., Pouponnot C., Mouriaux F., Eychene A., and Mascarelli F. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J. Biol. Chem. 278 (2003) 42409-42418
55. Gaggioli C., Robert G., Bertolotto C., Bailet O., Abbe P., Spadafora A., Bahadoran P., Ortonne J.P., Baron V., Ballotti R., and Tartare-Deckert S. Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. J. Invest. Dermatol 127 (2007) 400-410
56. Salvatore G., De Falco V., Salerno P., Nappi T.C., Pepe S., Troncone G., Carlomagno F., Melillo R.M., Wilhelm S.M., and Santoro M. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin. Cancer Res. 12 (2006) 1623-1629
57. Wu J., Richer J., Horwitz K.B., and Hyder S.M. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Res. 64 (2004) 2238-2244
58. Ishida A., Murray J., Saito Y., Kanthou C., Benzakour O., Shibuya M., and Wijelath E.S. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J. Cell. Physiol 188 (2001) 359-368
59. Meister B., Grunebach F., Bautz F., Brugger W., Fink F.M., Kanz L., and Mohle R. Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma. Eur. J. Cancer 35 (1999) 445-449
60. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 13 (1999) 9-22
61. Price D.J., Miralem T., Jiang S., Steinberg R., and Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12 (2001) 129-135
62. Tian X., Song S., Wu J., Meng L., Dong Z., and Shou C. Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem. Biophys. Res. Commun 286 (2001) 505-512
63. Bachelder R.E., Crago A., Chung J., Wendt M.A., Shaw L.M., Robinson G., and Mercurio A.M. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 61 (2001) 5736-5740
64. Handa A., Tokunaga T., Tsuchida T., Lee Y.H., Kijima H., Yamazaki H., Ueyama Y., Fukuda H., and Nakamura M. Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma. Int. J. Oncol 17 (2000) 291-295
65. Akagi M., Kawaguchi M., Liu W., McCarty M.F., Takeda A., Fan F., Stoeltzing O., Parikh A.A., Jung Y.D., Bucana C.D., Mansfield P.F., Hicklin D.J., and Ellis L.M. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br. J. Cancer 88 (2003) 796-802
66. Baba T., Kariya M., Higuchi T., Mandai M., Matsumura N., Kondoh E., Miyanishi M., Fukuhara K., Takakura K., and Fujii S. Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition. Gynecol. Oncol 105 3 (2007) 703-711
67. Ding H., Wu X., Roncari L., Lau N., Shannon P., Nagy A., and Guha A. Expression and regulation of neuropilin-1 in human astrocytomas. Int. J. Cancer 88 (2000) 584-592
68. Fakhari M., Pullirsch D., Abraham D., Paya K., Hofbauer R., Holzfeind P., Hofmann M., and Aharinejad S. Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma. Cancer 94 (2002) 258-263
69. Lantuejoul S., Constantin B., Drabkin H., Brambilla C., Roche J., and Brambilla E. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J. Pathol 200 (2003) 336-347
70. Parikh A.A., Liu W.B., Fan F., Stoeltzing O., Reinmuth N., Bruns C.J., Bucana C.D., Evans D.B., and Ellis L.M. Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer 98 (2003) 720-729
71. Fuh G., Garcia K.C., and de Vos A.M. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J. Biol. Chem. 275 (2000) 26690-26695
72. Soker S., Miao H.Q., Nomi M., Takashima S., and Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell Biochem 85 (2002) 357-368
73. Favier B., Alam A., Barron P., Bonnin J., Laboudie P., Fons P., Mandron M., Herault J.P., Neufeld G., Savi P., Herbert J.M., and Bono F. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 108 (2006) 1243-1250
74. Das B., Yeger H., Tsuchida R., Torkin R., Gee M.F., Thorner P.S., Shibuya M., Malkin D., and Baruchel S. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res. 65 (2005) 7267-7275
75. Kou R., SenBanerjee S., Jain M.K., and Michel T. Differential regulation of vascular endothelial growth factor receptors (VEGFR) revealed by RNA interference: interactions of VEGFR-1 and VEGFR-2 in endothelial cell signaling. Biochemistry 44 (2005) 15064-15073
76. List A.F., Glinsmann-Gibson B., Stadheim C., Meuillet E.J., Bellamy W., and Powis G. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp. Hematol 32 (2004) 526-535
77. Ochiumi T., Kitadai Y., Tanaka S., Akagi M., Yoshihara M., and Chayama K. Neuropilin-1 is involved in regulation of apoptosis and migration of human colon cancer. Int. J. Oncol 29 (2006) 105-116
78. Murga M., Fernandez-Capetillo O., and Tosato G. Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood 105 (2005) 1992-1999
79. Cejka D., Losert D., and Wacheck V. Short interfering RNA (siRNA): tool or therapeutic?. Clin. Sci. (Lond.) 110 (2006) 47-58
80. Ding Q., Stewart Jr. J., Olman M.A., Klobe M.R., and Gladson C.L. The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged. J. Biol. Chem. 278 (2003) 39882-39891
81. Lipscomb E.A., Dugan A.S., Rabinovitz I., and Mercurio A.M. Use of RNA interference to inhibit integrin (alpha6beta4)-mediated invasion and migration of breast carcinoma cells. Clin. Exp. Metastasis 20 (2003) 569-576
82. Lee T.H., Seng S., Li H., Kennel S.J., Avraham H.K., and Avraham S. Integrin regulation by vascular endothelial growth factor in human brain microvascular endothelial cells: role of alpha6beta1 integrin in angiogenesis. J. Biol. Chem. 281 (2006) 40450-40460
83. Klemke M., Weschenfelder T., Konstandin M.H., and Samstag Y. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J. Cell. Physiol 212 2 (2007) 368-374
84. Schwartz B., Melnikova V.O., Tellez C., Mourad-Zeidan A., Blehm K., Zhao Y.J., McCarty M., Adam L., and Bar-Eli M. Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene (2007)
85. Chetty C., Bhoopathi P., Joseph P., Chittivelu S., Rao J.S., and Lakka S. Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol. Cancer Ther 5 (2006) 2289-2299
86. Murai T., Miyazaki Y., Nishinakamura H., Sugahara K.N., Miyauchi T., Sako Y., Yanagida T., and Miyasaka M. Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration. J. Biol. Chem. 279 (2004) 4541-4550
87. Stoeck A., Keller S., Riedle S., Sanderson M.P., Runz S., Le Naour F., Gutwein P., Ludwig A., Rubinstein E., and Altevogt P. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem. J. 393 (2006) 609-618
88. Cao Y., Zhao Z., Gruszczynska-Biegala J., and Zolkiewska A. Role of metalloprotease disintegrin ADAM12 in determination of quiescent reserve cells during myogenic differentiation in vitro. Mol. Cell Biol. 23 (2003) 6725-6738
89. Kawaguchi N., Sundberg C., Kveiborg M., Moghadaszadeh B., Asmar M., Dietrich N., Thodeti C.K., Nielsen F.C., Moller P., Mercurio A.M., Albrechtsen R., and Wewer U.M. ADAM12 induces actin cytoskeleton and extracellular matrix reorganization during early adipocyte differentiation by regulating beta1 integrin function. J. Cell Sci. 116 (2003) 3893-3904
90. Petrovic N., Bhagwat S.V., Ratzan W.J., Ostrowski M.C., and Shapiro L.H. CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated endothelial cells. J. Biol. Chem. 278 (2003) 49358-49368
91. Sawai H., Okada Y., Funahashi H., Matsuo Y., Takahashi H., Takeyama H., and Manabe T. Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation. Mol. Cancer 4 (2005) 37
92. Li S., Dong W., Zong Y., Yin W., Jin G., Hu Q., Huang X., Jiang W., and Hua Z.C. Polyethylenimine-complexed plasmid particles targeting focal adhesion kinase function as melanoma tumor therapeutics. Mol. Ther 15 (2007) 515-523
93. Halder J., Kamat A.A., Landen Jr. C.N., Han L.Y., Lutgendorf S.K., Lin Y.G., Merritt W.M., Jennings N.B., Chavez-Reyes A., Coleman R.L., Gershenson D.M., Schmandt R., Cole S.W., Lopez-Berestein G., and Sood A.K. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 12 (2006) 4916-4924
94. Lee M.S., Ko S.G., Kim H.P., Kim Y.B., Lee S.Y., Kim S.G., Jong H.S., Kim T.Y., Lee J.W., and Bang Y.J. Smad2 mediates Erk1/2 activation by TGF-beta1 in suspended, but not in adherent, gastric carcinoma cells. Int. J. Oncol 24 (2004) 1229-1234
95. Duxbury M.S., Ito H., Benoit E., Waseem T., Ashley S.W., and Whang E.E. A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res. 64 (2004) 3987-3993
96. Duxbury M.S., Matros E., Ito H., Zinner M.J., Ashley S.W., and Whang E.E. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann. Surg 240 (2004) 667-674 discussion 675-666
97. Tan C., Cruet-Hennequart S., Troussard A., Fazli L., Costello P., Sutton K., Wheeler J., Gleave M., Sanghera J., and Dedhar S. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 5 (2004) 79-90
98. Fukuda T., Chen K., Shi X., and Wu C. PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motility, and survival. J. Biol. Chem. 278 (2003) 51324-51333
99. Lu P.Y., Xie F.Y., and Woodle M.C. Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol. Med 11 (2005) 104-113
100. Axelson H., Fredlund E., Ovenberger M., Landberg G., and Pahlman S. Hypoxia-induced dedifferentiation of tumor cells-a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin. Cell Dev. Biol. 16 (2005) 554-563
101. Hirota K., and Semenza G.L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol 59 (2006) 15-26
102. Fujiwara S., Nakagawa K., Harada H., Nagato S., Furukawa K., Teraoka M., Seno T., Oka K., Iwata S., and Ohnishi T. Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int. J. Oncol 30 (2007) 793-802
103. Nagy P., Arndt-Jovin D.J., and Jovin T.M. Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. Exp. Cell Res. 285 (2003) 39-49
104. Lapteva N., Yang A.G., Sanders D.E., Strube R.W., and Chen S.Y. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 12 (2005) 84-89
105. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., and Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
106. Liang Z., Yoon Y., Votaw J., Goodman M.M., Williams L., and Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 65 (2005) 967-971
107. Dekker R.J., van Thienen J.V., Rohlena J., de Jager S.C., Elderkamp Y.W., Seppen J., de Vries C.J., Biessen E.A., van Berkel T.J., Pannekoek H., and Horrevoets A.J. Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genes. Am. J. Pathol 167 (2005) 609-618
108. Bumcrot D., Manoharan M., Koteliansky V., and Sah D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2 (2006) 711-719
109. Dykxhoorn D.M., and Lieberman J. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. Annu. Rev. Biomed. Eng 8 (2006) 377-402
110. Oliveira S., Storm G., and Schiffelers R.M. Targeted delivery of siRNA. J. Biomed. Biotechnol 2006 (2006) 63675
111. McNamara II J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., Sullenger B.A., and Giangrande P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol 24 (2006) 1005-1015
112. Yang G., Thompson J.A., Fang B., and Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer. Oncogene 22 (2003) 5694-5701
113. Shu X., Wu W., Mosteller R.D., and Broek D. Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol. Cell Biol. 22 (2002) 7758-7768